Managing diabetes from first diagnosis: choosing well-tolerated therapies with durability.

Item

http://www.wikidata.org/entity/Q38020015

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Managing diabetes from first d ...... ted therapies with durability.

@en

type

Item

label

Managing diabetes from first d ...... ted therapies with durability.

@en

prefLabel

Managing diabetes from first d ...... ted therapies with durability.

@en

P1476

Managing diabetes from first d ...... ted therapies with durability.

@en

P2093

Davida F Kruger

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Secondary failure of metformin monotherapy in clinical practice.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

P304

4S-11S; quiz 12S

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0145721712450619

http://www.w3.org/2001/XMLSchema#string

P433

4 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22713263

http://www.w3.org/2001/XMLSchema#string